Aigen Investment Management LP Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aigen Investment Management LP purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 657 shares of the biopharmaceutical company’s stock, valued at approximately $577,000.

Several other large investors also recently made changes to their positions in the business. Assetmark Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.7% during the fourth quarter. Assetmark Inc. now owns 92,171 shares of the biopharmaceutical company’s stock worth $80,953,000 after purchasing an additional 1,552 shares in the last quarter. Quest Partners LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $991,000. STF Management LP boosted its holdings in Regeneron Pharmaceuticals by 4.1% in the 4th quarter. STF Management LP now owns 1,826 shares of the biopharmaceutical company’s stock worth $1,604,000 after acquiring an additional 72 shares during the period. Trexquant Investment LP purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $5,174,000. Finally, Corient Private Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 8.2% during the fourth quarter. Corient Private Wealth LLC now owns 33,561 shares of the biopharmaceutical company’s stock worth $29,476,000 after purchasing an additional 2,537 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on REGN. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. TD Cowen raised their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Truist Financial reiterated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $989.36.

Regeneron Pharmaceuticals Trading Down 0.5 %

Shares of REGN stock opened at $979.25 on Thursday. The firm has a market capitalization of $107.90 billion, a PE ratio of 29.06, a price-to-earnings-growth ratio of 2.05 and a beta of 0.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The stock has a fifty day moving average of $943.97 and a two-hundred day moving average of $912.75.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold 54,925 shares of company stock valued at $53,649,186 over the last 90 days. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.